In This Article:
TruBridge TBRG shares ended the last trading session 6.4% higher at $27.16. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 21.1% gain over the past four weeks.
TruBridge recorded a strong price rise on investors’ optimism surrounding the company’s latest cooperation agreements with Pinetree Capital Ltd. and L6 Holdings Inc. and with Ocho Investments LLC. Following the agreement, TruBridge has appointed Jerry Canada and Dris Upitis to its Board of Directors, effective February 11, 2025. Additionally, TruBridge has also announced several initiatives reflecting its ongoing commitment to strong corporate governance and stockholder value creation.
This healthcare information technology company is expected to post quarterly earnings of $0.58 per share in its upcoming report, which represents a year-over-year change of +61.1%. Revenues are expected to be $84.53 million, down 1.6% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For TruBridge, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on TBRG going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
TruBridge is part of the Zacks Medical Info Systems industry. Fulgent Genetics, Inc. FLGT, another stock in the same industry, closed the last trading session 0.7% higher at $16.27. FLGT has returned -9.9% in the past month.
Fulgent Genetics' consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.12. Compared to the company's year-ago EPS, this represents a change of -142.9%. Fulgent Genetics currently boasts a Zacks Rank of #3 (Hold).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
TruBridge, Inc. (TBRG) : Free Stock Analysis Report
Fulgent Genetics, Inc. (FLGT) : Free Stock Analysis Report